Cramer: Apple Is Th...
Health Care: Drugs
AEterna Zentaris Inc. (AEZS: NASDAQ)
$0.47 -0.01 | -2.10%
06/01/12 - 03:59 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 36.05M | 27.70M | 63.24M | 38.48M |
| Cost of Sales | 26.32M | 19.61M | 13.00M | 24.76M |
| Gross Operating Profit | 9.74M | 8.78M | 50.24M | 13.72M |
| Selling, General, and Administrative Expenses | 16.17M | 11.88M | 16.04M | 17.32M |
| Research & Development | 24.52M | 20.55M | 44.22M | 57.10M |
| Operating Income before D & A (EBITDA) | -30.95M | -23.64M | -10.02M | -60.71M |
| Depreciation & Amortization | 1.24M | 1.59M | 14.34M | 1.67M |
| Interest Income | 6.24M | 207.00K | 349.00K | 868.00K |
| Other Income - Net | 0.00 | 1.80M | -1.11M | 2.99M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -25.96M | -23.22M | -24.72M | -58.52M |
| Interest Expense | 8.00K | 0.00 | 5.00K | 118.00K |
| Pre-Tax Income | -25.96M | -23.22M | -24.72M | -58.64M |
| Income Taxes | 1.10M | 0.00 | 0.00 | 1.18M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -27.07M | -23.22M | -24.72M | -59.82M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -27.07M | -23.22M | -24.72M | -59.82M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -27.07M | -23.22M | -24.72M | -59.82M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-27.07M | -23.22M | -25.13M | -59.82M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -27.07M | -23.22M | -24.72M | -59.82M |
| Basic EPS from Continuing Ops. | -0.29 | -0.31 | -0.43 | -1.12 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.29 | -0.31 | -0.43 | -1.12 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.29 | -0.31 | -0.43 | -1.12 |
| Basic Normalized Net Income/Share | -0.29 | -0.31 | -0.44 | -1.12 |
| EPS fr Continuing Ops. | -0.29 | -0.31 | -0.43 | -1.12 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.29 | -0.31 | -0.43 | -1.12 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.29 | -0.31 | -0.43 | -1.12 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.29 | -0.31 | -0.44 | -1.12 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with AEZS
- Portfolio NameUser Type
- UserMillion Dollar Portfolio
- Userwright stocks
- UserSMITTY
- UserFiuza 1
- Userherb's portfolio
- Contributor10 Pharma Stocks Under $3
- UserMy Portfolio
- Contributor4 Biotech Penny Stocks to Buy
- Contributor10 Cheap Stocks to Buy for ...
- UserBunny Money
Latest AEZS Headlines from TheStreet
- ASCO '12: Colon Cancer Drugs Good (Roche) and Very Bad (Keryx Pharma) 06.03.12 | 06:06 am
- Keryx: Lessons From a Drug Failure 04.02.12 | 12:04 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 04.02.12 | 09:04 am
- Keryx: Perifosine Colon Cancer Trial Fails 04.02.12 | 07:04 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- As Keryx, Aeterna Shares Surge, Investing Writer's Credibility Questioned 03.06.12 | 01:03 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 03.06.12 | 08:03 am
- Keryx Rises With Hopes on Cancer Drug 03.06.12 | 05:03 am
- 10 Biotech Stock Predictions for 2012 12.20.11 | 11:12 am
- Biotech Stock Mailbag: Prostate Cancer Drug Reaction 11.04.11 | 05:11 am
Press Releases for AEZS
- Aeterna Zentaris: Article On Perifosine As Potential Novel Approach To The Treatment Of Mesothelioma Published In Plos One - PR Newswire 05.31.12 | 07:05 am
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In AEterna Zentaris Inc. To Contact The Firm - PR Newswire 05.25.12 | 07:05 pm
- Aeterna Zentaris Receives Notification From NASDAQ Relating To Minimum Bid Price - PR Newswire 05.16.12 | 04:05 pm
- Aeterna Zentaris Presents Preclinical Data For Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, At AACR Meeting - PR Newswire 04.03.12 | 07:04 am
- Aeterna Zentaris Announces Top-Line Data From The Perifosine Phase 3 Trial In Refractory Advanced Colorectal Cancer - PR Newswire 04.02.12 | 07:04 am
- Aeterna Zentaris To Present At Needham Healthcare Conference In New York - PR Newswire 03.29.12 | 07:03 am
- Aeterna Zentaris To Announce Fourth Quarter And Full Year 2011 Financial And Operating Results On March 27, 2012 - PR Newswire 03.20.12 | 07:03 am
- Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial In Cancer Cachexia With Aeterna Zentaris' Ghrelin Agonist, AEZS-130 - PR Newswire 03.08.12 | 07:03 am
- Aeterna Zentaris To Present At Cowen And Company 32nd Annual Health Care Conference In Boston - PR Newswire 02.29.12 | 07:02 am
- Aeterna Zentaris To Present At BIO CEO Investor And RBC Capital Markets Global Healthcare Conferences In New York - PR Newswire 02.07.12 | 07:02 am
Partner Headlines for AEZS
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris - Seeking Alpha 03.02.12 | 05:03 pm
- 5 High-Risk, High-Reward Biopharma Stocks - Seeking Alpha 02.14.12 | 09:02 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 02.01.12 | 09:02 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 01.26.12 | 09:01 am
- 3 Biotechs Hopefully To Get Rich Or Die Trying - Seeking Alpha 01.04.12 | 08:01 am
- 7 Stocks Below $10 That Analysts Expect To Double - Seeking Alpha 12.05.11 | 08:12 am
- Biotechs And Their Trials By Fire - Seeking Alpha 11.07.11 | 09:11 am
- Keryx Biopharmaceuticals: Volatility Could Potentially Produce Monetary Gains - Seeking Alpha 10.23.11 | 09:10 am
